Halozyme calls second tranche of warrants from January 2004 financing

By Elaine Rigoli

Tampa, Fla., Aug. 9 - Halozyme Therapeutics, Inc. said it has sent notices of redemption to warrant holders covering about 1.9 million shares of its common stock.

For 30 days following the notice, those warrant holders may exercise their warrants for $1.75 per share. If all affected warrants are exercised, the company would receive gross proceeds of about $3.3 million.

After 30 days, Halozyme may buy any of the affected warrants that are not exercised for $0.01 per share.

Halozyme is a biopharmaceutical company based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.